Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 869-883

  Verhoef, Talitha I ^a   Redekop, William K ^b   Veenstra, David L ^c   Thariani, Rahber ^a   Beltman, Peter A ^a   Van Schie, Rianne M F ^a   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

atrial fibrillation; cost effectiveness; coumarins; CYP2C9; health economics; pharmacogenetics; phenprocoumon; VKORC1

Indexed keywords

PHENPROCOUMON;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYP2C9 GENE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; NETHERLANDS; PHARMACOGENETICS; QUALITY ADJUSTED LIFE YEAR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VKORC1 GENE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GENOTYPE; HUMANS; MARKOV CHAINS; PHARMACOGENETICS; PHENPROCOUMON; WARFARIN;

EID: 84878853471     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.74     Document Type: Article

References (37)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126(Suppl. 3), S204-S233 (2004).
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008).
3. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J. Thromb. Thrombolysis 21(1), 73-77 (2006). (Pubitemid 43231132)
4. Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr. Pharm. Des. 16(2), 187-203 (2010).
5. Rosendaal FR. The scylla and charybdis of oral anticoagulant treatment. N. Engl. J. Med. 335(8), 587-589 (1996). (Pubitemid 26272315)
6. Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio J. Thromb. Thrombolysis 27(3), 293-299 (2009).
7. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414-1419 (2007). (Pubitemid 47052441)
8. Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch. Intern. Med. 169(13), 1203-1209 (2009).
9. Bodin L, Verstuyft C, Tregouet DA et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106(1), 135-140 (2005). (Pubitemid 40967184)
10. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
11. Consortium IWP, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
12. van Schie RM, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. 32(15), 1909-1917 (2011).
13. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). (Pubitemid 350179221)
14. Hillman MA, Wilke RA, Yale SH et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3(3), 137-145 (2005).
15. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2008). (Pubitemid 351272635)
16. Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997-2005 (2012).
17. van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
18. French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
19. Do EJ, Lenzini P, Eby CS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2012).
20. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1), 61-74 (2010).
21. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring Clin. Pharmacol. Ther. 79(6), 511-520 (2006). (Pubitemid 43817947)
22. Fang MC, Go AS, Chang Y et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am. J. Med. 120(8), 700-705 (2007). (Pubitemid 47176507)
23. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69(3), 236-239 (1993). (Pubitemid 23069000)
24. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 179(3), 235-244 (2008).
25. Howard R, Leathart JB, French DJ et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clin. Chim. Acta 412(23-24), 2063-2069 (2011).
26. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of stroke in The Netherlands: the impact of stroke services. Int. J. Technol. Assess. Health Care 22(4), 518-524 (2006). (Pubitemid 44622974)
27. Verhoef TI, Redekop WK, van Schie RM et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 13(12), 1405-1417 (2012).
28. Verhoef TI, Redekop WK, Darba J et al. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 11(7), 989-1002 (2010).
29. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 2(5), 429-436 (2009).
30. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther. 86(5), 540-547 (2009).
31. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150(2), 73-83 (2009).
32. Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 22(17), 1097-1107 (2004). (Pubitemid 39665341)
33. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
34. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
35. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343, d6333 (2011).
36. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123(22), 2562-2570 (2011).
37. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745), 975-983 (2010).